Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

A Study of Eciskafusp Alfa and Bacillus Calmette-Guérin (BCG) in Participants with High-Risk Bladder Cancer Unresponsive to BCG Treatment Ended

2024-515410-41-00 BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder 9 2025-04-01
Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo®… Ended

2023-507865-24-00 Advanced (unresectable/metastatic) melanoma 5 2025-03-28
Intralesional Cemiplimab for Adult Patients with Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma Ended

2024-511440-76-00 Cutaneous Squamous Cell Carcinoma 1 2025-03-20
Trial to assess the safety and antitumor activity of GEN1057 on malignant solid tumors Ended

2024-513563-75-00 Metastatic or advanced malignant solid tumors 1 2025-03-20
A Phase I study to evaluate the safety and dosimetry of 68Ga-OncoCAIX in patients with CAIX-positive cancer Ended

2024-515607-19-00 Patients with suspected clear cell renal cell carcinoma 1 2025-03-19
A Phase I study to evaluate the safety and dosimetry of 68Ga-OncoACP3 in patients with prostate cancer Ended

2024-515608-38-00 Patients with prostate cancer with: -suspected metastas 1 2025-03-19
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together with Either Pembrolizumab, Standard Therapies, or Both, in Adults with Solid T… Ended

2023-505084-37-00 Advanced Solid Tumors 7 2025-03-17
AKTive-001: A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients with Advanced Solid Tumors with AKT1 E17K Mutation Ended

2024-515391-12-00 Advanced Solid Tumors with AKT1 E17K Mutation 1 2025-03-15
Phase 1/2 Study of Cobolimab plus Dostarlimab in Pediatric and Young Adult Participants with Newly Diagnosed and Relapsed/Refractory Tumors Ended

2024-511350-41-00 Relapsed/Refractory Tumors 9 2025-03-13
A Study of ZL-1218 with or without Pembrolizumab in Subjects with Advanced Solid Tumor Cancers to Find a Suitable Dose and to Test How Diffe… Ended

2022-503102-20-00 Advanced solid tumors 1 2025-03-10
A Study of ZW171 in Participants with Advanced or Metastatic Mesothelin Expressing Cancers Ended

2024-511119-11-00 Advanced or metastatic ovarian cancer, NSCLC, pancreati 1 2025-03-07
A Phase 1 Study of PRT7732, an Oral SMARCA2 Degrader, in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation Ended

2024-512380-32-00 esophageal, gastric, or gastroesophageal junction adeno 1 2025-03-03
A phase I/II trial of D,L-MEthadone and mFOLFOX6 in treatment of advanced colorectal cancer (MEFOX) Ended

2024-519509-37-00 Patients with advanced, histologically confirmed, metas 9 2025-02-25
Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-1664 in Participants with Advanced … Ended

2024-511259-16-00 Advanced Solid Tumors 1 2025-02-24
An Open-Label, Multicentre Phase 1b/2a Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32b), in Combination wi… Ended

2024-512670-10-00 Unresectable or Metastatic Melanoma 9 2025-02-13
A study to evaluate S227928 as a Single Agent and in Combination with Venetoclax in Patients with R/R AML, MDS/AML, or CMML Ended

2024-514356-33-00 "Patients with Relapsed/Refractory (R/R) Acute Myeloid 7 2025-02-11
N/A Ended

2024-513121-22-00 Recurrent or Metastatic Head and Neck Squamous Cell Car 4 2025-02-04
Study of Repotrectinib and CYP450 probe Cocktail in Patients with locally advanced or Metastatic Tyrosine Kinase Inhibitors (TKI)-Pretreated… Ended

2024-511030-12-00 Non-small Cell Lung Cancer (NSCLC) 3 2025-02-03
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Bosutinib… Ended

2024-516489-12-00 myeloid leukemia 2 2025-01-31
A first-in-human trial of safety and efficacy of GEN1078 in participants with solid tumors. Ended

2024-515752-21-00 Malignant solid tumors 7 2025-01-29
A trial to learn how well NMS-01940153E works in combination with atezolizumab and priming administration of decitabine or with atezolizumab… Ended

2024-516737-12-00 Unresectable Hepatocellular Carcinoma (HCC) 4 2025-01-28
A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or togethe… Ended

2023-508998-85-00 Metastatic pancreatic ductal adenocarcinoma (mPDAC) 1 2025-01-28
Phase I/II study to determine the safety and efficacy of Ribociclib in combination with hormone therapy and hypofractionated radiotherapy in… Ended

2022-501527-24-00 breast cancer 9 2025-01-24
M1774 (oral ATR inhibitor) in Combination with PLX038 (Topo1 inhibitor) with dose expansion cohorts in patients with advanced solid tumors Ended

2023-505431-12-00 Patients with pretreated, metastatic or locally advance 1 2025-01-20